Similar Search Results

Non‐financial performance measures in the Canadian biotechnology industry

Cumby, Judy; Conrod, Joan - In: Journal of Intellectual Capital 2 (2001) 3, pp. 261-272

developments and their applicability to the biotechnology industry. Examines the externally published information of public … Canadian biotechnology companies with a view to the development of measures appropriate for evaluating corporate performance … effectiveness of communication regarding performance in the Canadian biotechnology industry. …

Persistent link: https://www.econbiz.de/10014875251

Drivers of voluntary intellectual capital disclosure in listed biotechnology companies

White, Gregory; Lee, Alina; Tower, Greg - In: Journal of Intellectual Capital 8 (2007) 3, pp. 517-537

Purpose – The paper seeks to investigate the key drivers and level of voluntary disclosures in biotechnology company … disclosures in a large sample of listed biotechnology companies, and tests the relationship between voluntary disclosures of … relationship. Research limitations/implications – The implications of this research are that smaller biotechnology companies …

Persistent link: https://www.econbiz.de/10014875454

The nature and extent of voluntary intellectual capital disclosures by Australian and UK biotechnology companies

White, Gregory; Lee, Alina; Yuningsih, Yuni; Nielsen, … - In: Journal of Intellectual Capital 11 (2010) 4, pp. 519-536

disclosures (ICD) by UK and Australian biotechnology companies. The motivating research question was whether the nature and extent … effect was demonstrated in relation to the “nature” of ICD by UK and Australian biotechnology companies. Interestingly, mean …

Persistent link: https://www.econbiz.de/10014875569

Competency‐based benchmarking

Ahn, Mark J.; Dornbusch, Daniel - In: Benchmarking: An International Journal 11 (2004) 2, pp. 190-202

Flawless product launches are critical success factors for biopharmaceutical companies due to increasing financial and technological risks. Industry benchmarking is widely used for managing biopharmaceutical product launch planning. However, while industry benchmarking may achieve operational...

Persistent link: https://www.econbiz.de/10014683236

Bioethical analysis of the Promethean and biophilia global biobusiness

Dean Parhizgar, Kamal; Parhizgar, Suzan; Parhizgar, Fuzhan - In: Competitiveness Review: An International Business Journal 16 (2006) 2, pp. 170-184

In this article our objective is to do a very deep analysis into biobusinesses and bioethics in order to identify holistic views concerning business enterprises in biopharmaceutical and biotechnological industries. We are arguing that biobusinesses and biotechnologies are not error free because...

Persistent link: https://www.econbiz.de/10014702341

Organisational innovativeness in Estonian biotechnology organisations

Jaakson, Krista; Tamm, Dorel; Hämmal, Gerli - In: Baltic Journal of Management 6 (2011) 2, pp. 205-226

Purpose – The biotechnology sector provides business‐to‐business service and continuous innovation is an imperative for … biotechnology organisations in order to survive. The aim of this paper is to outline the elements in Estonian biotechnology … were carried out in 15 biotechnology organisations in Estonia. The questions were divided into five categories: strategic …

Persistent link: https://www.econbiz.de/10014685572

Biotech spin-off business models for the internationalization strategy

Bialek-Jaworska, Anna; Gabryelczyk, Renata - In: Baltic Journal of Management 11 (2016) 4, pp. 380-404

based on a multiple case study analysis including business models of seven biotechnology spin-offs traded on the Warsaw …

Persistent link: https://www.econbiz.de/10014685971

Emerging economic sectors in the third millennium: life sciences to dominate US economy by 2100

Molitor, Graham T.T. - In: Foresight 2 (2000) 5, pp. 507-513

This article, third in a series of six, describes Life Sciences Era activities. Life sciences, rapidly gaining momentum, will begin to dominate US economic activity by 2100, then predominate well into the following century (see Figure 1). Massive advances will follow as the 140 000 genes, and 3...

Persistent link: https://www.econbiz.de/10014742716

Managing risks in biotechnology: can we learn from nuclear power?

Gaivoronskaia, Galina; Erik Solem, Knut - In: Foresight 3 (2001) 1, pp. 33-45

The potential of biotechnology to cure disease and feed the Third World has not eased public disquiet about its safety …

Persistent link: https://www.econbiz.de/10014742741

Innovation challenges for European agriculture

de Wilt, J.G.; Diederen, P.J.M.; Butter, M.; Tukker, A. - In: Foresight 3 (2001) 4, pp. 341-352

breeding crops and animals using biotechnology, for markets as diverse as power generation and pharmaceuticals. For Europe …

Persistent link: https://www.econbiz.de/10014742765